company background image
ZYXI

Zynex NasdaqGS:ZYXI Stock Report

Last Price

US$9.38

Market Cap

US$337.8m

7D

-1.8%

1Y

34.6%

Updated

31 May, 2023

Data

Company Financials +

ZYXI Stock Overview

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation.

ZYXI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Zynex, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zynex
Historical stock prices
Current Share PriceUS$9.38
52 Week HighUS$17.25
52 Week LowUS$6.56
Beta0.59
1 Month Change-29.69%
3 Month Change-25.61%
1 Year Change34.58%
3 Year Change-48.38%
5 Year Change189.02%
Change since IPO339.06%

Recent News & Updates

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Mar 30
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Jan 23
Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Recent updates

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Mar 30
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Jan 23
Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Short Squeeze Candidate With Low PEG Ratio: Zynex

Oct 05

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12
Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13
Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23
Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

Zynex: Turnaround Nears Inevitable End - Largest Payor Cuts TENS Reimbursement, May Eliminate Earnings

Dec 10

Zynex: A Fact Finding Mission

Sep 03

Zynex Took A Back Seat Due To Covid-19

Aug 22

Zynex, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

What Does Zynex, Inc.'s (NASDAQ:ZYXI) Share Price Indicate?

Mar 09
What Does Zynex, Inc.'s (NASDAQ:ZYXI) Share Price Indicate?

Have Insiders Been Selling Zynex, Inc. (NASDAQ:ZYXI) Shares?

Feb 16
Have Insiders Been Selling Zynex, Inc. (NASDAQ:ZYXI) Shares?

Is There More To The Story Than Zynex's (NASDAQ:ZYXI) Earnings Growth?

Feb 02
Is There More To The Story Than Zynex's (NASDAQ:ZYXI) Earnings Growth?

Is Zynex, Inc. (NASDAQ:ZYXI) Popular Amongst Insiders?

Jan 20
Is Zynex, Inc. (NASDAQ:ZYXI) Popular Amongst Insiders?

Zynex announces filing of patent for sepsis monitor

Jan 14

Zynex: Operating Inefficiencies And Gross-To-Net Challenges Place Ceiling On Scalability

Jan 12

Zynex announces second utility patent for its blood volume monitor

Jan 06

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Jan 05
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Does Zynex (NASDAQ:ZYXI) Deserve A Spot On Your Watchlist?

Dec 23
Does Zynex (NASDAQ:ZYXI) Deserve A Spot On Your Watchlist?

Is Weakness In Zynex, Inc. (NASDAQ:ZYXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Dec 08
Is Weakness In Zynex, Inc. (NASDAQ:ZYXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Should You Investigate Zynex, Inc. (NASDAQ:ZYXI) At US$13.62?

Nov 24
Should You Investigate Zynex, Inc. (NASDAQ:ZYXI) At US$13.62?

Shareholder Returns

ZYXIUS Medical EquipmentUS Market
7D-1.8%-1.2%1.0%
1Y34.6%2.7%-0.2%

Return vs Industry: ZYXI exceeded the US Medical Equipment industry which returned 2.7% over the past year.

Return vs Market: ZYXI exceeded the US Market which returned -0.2% over the past year.

Price Volatility

Is ZYXI's price volatile compared to industry and market?
ZYXI volatility
ZYXI Average Weekly Movement14.1%
Medical Equipment Industry Average Movement7.6%
Market Average Movement6.5%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: ZYXI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ZYXI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1996900Thomas Sandgaardhttps://www.zynex.com

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products.

Zynex, Inc. Fundamentals Summary

How do Zynex's earnings and revenue compare to its market cap?
ZYXI fundamental statistics
Market CapUS$337.84m
Earnings (TTM)US$17.24m
Revenue (TTM)US$169.25m

19.8x

P/E Ratio

2.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZYXI income statement (TTM)
RevenueUS$169.25m
Cost of RevenueUS$33.99m
Gross ProfitUS$135.26m
Other ExpensesUS$118.02m
EarningsUS$17.24m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.47
Gross Margin79.92%
Net Profit Margin10.19%
Debt/Equity Ratio14.4%

How did ZYXI perform over the long term?

See historical performance and comparison